In the first instance, Bindbridge is looking to develop a new broad spectrum non specific herbicide that can replace ...

Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targetsStudy further ...

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and ...

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...

Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...

Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...

Add Yahoo as a preferred source to see more of our stories on Google. Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted ...

SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial ...